P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

Inclusion Criteria: * Subject with HCC who meet the following criteria 1. Subjects diagnosed as having typical HCC on dynamic CT, or dynamic MRI performed within 8 weeks before surgery, or subjects who diagnosed HCC by pathology after surgery resection; 2. Subjects with the primary occurrence HCC ; 3. Subjects with the HCC related to hepatitis B virus (HBV) ; * Subject who have undergone surgical liver reaction within 8 weeks prior to study entry. * Subjects showing a complete cure shows no findings suggestive of recurrence or remnant. ; * Subject who are able to begin treatment with the study drug within 12 weeks after liver surgery resection. ; * Subjects confirmed of satisfying the following conditions based on the screening performed at enrollment: Positive for HBsAg/ Undetectable HBV DNA, with or without current anti HBV treatment/ Grade A on Child-Pugh classification; * Normal fundoscopic examination by ophthalmologist at screening; * ECOG 0 to 1 ; Exclusion Criteria: * Subjects positive for anti-HCV ; * Subjects showing vascular invasion of HCC on imaging diagnosis ; * Subjects who have uncontrolled hypertension; * Subjects with a history of pneumonitis or interstitial lung disease . cardiac arrest . an active infection requiring therapy .; * Diabetes mellitus with HbA1c ≥ 7.4% with insulin treatment;